Rapport Therapeutics (NASDAQ:RAPP) Stock Jumps 7.5% Following Insider Buying Activity

Key Points

• Rapport Therapeutics shares rose 7.5% after CFO Troy Ignelzi purchased 5,500 shares for $143,550, increasing his direct holdings by 55%.
• Analysts remain broadly bullish, with a consensus “Buy” rating and an average price target of $68.36; several firms recently raised targets as RAP-219 advances toward Phase 3 after positive Phase 2 bipolar-mania results.
• Despite the optimism, RAP-219 remains experimental and will require additional time and funding for Phase 3 trials, while Rapport remains unprofitable and recently missed quarterly EPS expectations.

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) was up 7.5% during trading on Thursday after an insider bought additional shares in the company. The company traded as high as $26.98 and last traded at $26.9330. Approximately 111,919 shares changed hands during trading, a decline of 72% from the average daily volume of 400,062 shares. The stock had previously closed at $25.06.

Specifically, CFO Troy Ignelzi purchased 5,500 shares of the stock in a transaction dated Wednesday, October 21st. The shares were purchased at an average cost of $26.10 per share, with a total value of $143,550.00. Following the completion of the acquisition, the chief financial officer directly owned 15,500 shares in the company, valued at $404,550. This trade represents a 55.00% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on RAPP shares. TD Cowen reaffirmed a "buy" rating on shares of Rapport Therapeutics in a report on Tuesday. UBS Group began coverage on shares of Rapport Therapeutics in a research report on Thursday, October 15th. They set a "buy" rating and a $71.00 price objective on the stock. William Blair began coverage on shares of Rapport Therapeutics in a research note on Tuesday, July 28th. They set an "outperform" rating for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Rapport Therapeutics in a research note on Thursday, October 15th. Finally, Wolfe Research assumed coverage on Rapport Therapeutics in a research report on Thursday, October 15th. They set an "outperform" rating and a $50.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $68.36.

Key Headlines Impacting Rapport Therapeutics

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 advanced toward Phase 3. Rapport reported that RAP-219 met both Phase 2 endpoints in bipolar mania, showing statistically significant placebo-adjusted improvements in manic symptoms. The company plans to begin Phase 3 development, potentially increasing the program’s value and expanding its addressable market. Rapport plans Phase III bipolar mania trials
• Positive Sentiment: Analysts raised or maintained bullish price targets. JonesTrading increased its target from $50 to $82, while Raymond James raised its target to $86. BTIG also increased its target, and HC Wainwright reaffirmed a Buy rating with a $66 target. The revisions reflect expectations that RAP-219 could become a significant commercial opportunity, with potential peak sales estimates near $1 billion. BTIG raises Rapport price target
• Positive Sentiment: CFO Troy Ignelzi bought 5,500 shares at an average price of $26.10, investing $143,550 and increasing his direct ownership by 55%. The open-market purchase may be viewed as a signal of management confidence in the company’s outlook. Rapport CFO stock purchase
• Neutral Sentiment: The Phase 2 results support further development but do not eliminate clinical, regulatory, financing, or commercialization risks. RAP-219 is still an experimental therapy, and Phase 3 trials will require additional time and capital.
• Negative Sentiment: Some reports characterized the bipolar-mania results as a narrow win relative to initial expectations. Rapport also remains unprofitable and previously reported quarterly EPS below consensus, which could limit upside if development costs rise or future data disappoint. Rapport bipolar data analysis

Rapport Therapeutics Trading Up 10.4%

The stock has a 50 day simple moving average of $39.86 and a 200-day simple moving average of $39.07. The firm has a market cap of $1.33 billion, a PE ratio of -9.09 and a beta of 1.22.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.07). On average, equities research analysts expect that Rapport Therapeutics, Inc. will post -4.09 EPS for the current year.

Institutional Trading of Rapport Therapeutics

Institutional investors have recently bought and sold shares of the stock. Engineers Gate Manager LP purchased a new position in shares of Rapport Therapeutics during the second quarter valued at approximately $888,000. Wellington Management Group LLP raised its holdings in shares of Rapport Therapeutics by 11.2% in the second quarter. Wellington Management Group LLP now owns 86,988 shares of the company's stock valued at $3,625,000 after acquiring an additional 8,757 shares in the last quarter. Artia Global Partners LP purchased a new stake in shares of Rapport Therapeutics in the 2nd quarter worth approximately $5,772,000. Bank of America Corp DE purchased a new position in Rapport Therapeutics during the second quarter valued at approximately $3,170,000. Finally, Jupiter Topco LLC bought a new position in Rapport Therapeutics in the second quarter worth approximately $574,000.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company's approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport's lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.